Instem plc Issue of Equity (7957A)

TIDMINS

RNS Number : 7957A

Instem plc

09 June 2016

Instem plc

("Instem", the "Company" or the "Group")

Issue of Equity and Total Voting Rights

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that, following the exercise of share options by an employee, 8,500 ordinary shares of 10p each in the Company ("Ordinary Shares") have been issued.

Application will be made to the London Stock Exchange for the admission of the 8,500 new Ordinary Shares to trading on AIM and admission is expected to take place at 8.00am on 15 June 2016.

Total Voting Rights

Following the issue and allotment of the above new Ordinary Shares, the Company's issued share capital comprises 15,710,952 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 15,710,952.

The figure of 15,710,952 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

 
 Instem plc                                 +44 (0) 1785 825 600 
 Phil Reason, CEO 
 Nigel Goldsmith, CFO 
 
 N+1 Singer (Nominated Adviser & Broker)    +44 (0) 20 7496 3000 
 Richard Lindley 
 Nick Owen 
 James White 
 
 Walbrook Financial PR                      +44 (0) 20 7933 8000 
 Paul Cornelius                             instem@walbrookpr.com 
 Helen Cresswell 
 Sam Allen 
 Paul Whittington

About Instem plc

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 450 clients through full service offices in the United States, the United Kingdom, India and China, with additional presence in France and Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEQKLFBQQFXBBF

(END) Dow Jones Newswires

June 09, 2016 12:32 ET (16:32 GMT)

Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024